Gesine Saher, PhD, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany, discusses lipid-based therapy as a new avenue for therapeutic opportunities for multiple sclerosis (MS), particularly the potential of dietary approaches. Permanent disabilities in demyelinating diseases such as MS are caused by progressive neuron damage. Together with the adverse effects of the proinflammatory environment, neurons are at risk of suffering energy deficits. An evident approach to the energy deficits would be to increase glucose levels, but studies in animal models have shown that it caused the opposite effect and exacerbated the disease. Alternative strategies to fill the “”brain energy gap”” are to increase dietary lipids by following a ketogenic diet, intermittent fasting, or derivatives of ketone bodies. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.